IN Brief:
- Singapore has authorised Aleph Farms’ cultivated Thin-Cut Steak.
- The hybrid product combines cultivated cattle cells with soy and wheat proteins.
- Initial restaurant volumes are expected during 2027 before regional capacity increases.
Aleph Farms has received Singapore Food Agency approval for its cultivated Thin-Cut Steak, clearing the product for sale almost four years after the company submitted its application in September 2022.
The Israeli business plans to begin with selected restaurant partners during the first half of 2027. Commercial timing depends on bringing a Singapore production line into operation and completing the supply, quality, and customer preparations needed to move from regulatory clearance to repeatable service.
The approved product combines cultivated, non-genetically modified and non-immortalised Black Angus cattle cells with a plant-protein matrix made from soy and wheat. It will be sold under the Aleph Cuts brand, making allergen control and hybrid-product labelling part of the launch alongside the cultivated component.
Aleph Farms established a Singapore entity as an Asia-Pacific hub and is working with contract manufacturer Cell Agritech on regional production. The partner-led model limits the need for Aleph Farms to own every commercial facility, but it places more weight on technology transfer, oversight, and process consistency.
Singapore requires novel foods to obtain pre-market approval before they can be supplied or manufactured for supply. Applicants must provide scientific evidence covering potential hazards, including toxicity, allergenicity, the safety of the production method, and dietary exposure.
The approval therefore applies to an assessed product and manufacturing basis rather than giving the company unrestricted freedom to change its process. Singapore’s guidance states that changes capable of affecting the original safety assessment may require further regulatory consideration.
That condition is significant for cultivated meat because scale-up programmes are built around changes to cell performance, media use, vessel operation, yield, and downstream recovery. A cost-saving modification cannot be treated as purely commercial when it alters the evidence used to establish safety or product identity.
The hybrid format reduces the proportion of cultivated material required in each portion and allows the plant matrix to contribute structure. It also creates conventional formulation challenges around soy and wheat allergens, texture, flavour, cooking behaviour, nutrition, and batch-to-batch consistency.
The company has not disclosed the planned output of the Singapore line, its initial selling price, or the restaurants selected for launch. It has said early volumes will be modest, with capacity expected to increase through 2028.
A restaurant introduction provides a controlled route into the market. Volumes can be limited, preparation methods can be specified, and customer feedback can be collected directly, but the format still requires reliable cold storage, traceability, shelf-life control, and consistent product release.
Manufacturing cultivated beef involves more than growing cells. Cell banks, culture inputs, vessels, harvesting, formulation, packaging, and distribution must remain within approved specifications, while deviations need to be investigated through a food-grade quality system.
Cleaning and environmental monitoring will be central to the partner site. Cultivation equipment has to manage contamination risks without relying on operating practices that undermine yield, while downstream handling must protect the material as it is combined with plant ingredients and formed into the finished product.
Partner manufacturing can reduce capital requirements, but it also divides responsibility. Aleph Farms must provide process knowledge and product standards, while Cell Agritech must demonstrate that local equipment, staff, utilities, and controls can reproduce the approved outcome over repeated batches.
Singapore’s decision follows Aleph Farms’ earlier approval in Israel, giving the company two authorised markets for cultivated beef. Approval in more than one jurisdiction can support future applications, but each regulator applies its own legal framework and does not automatically adopt another authority’s conclusion.
The commercial hurdle remains separate from the safety decision. Cultivated meat producers need sufficient yield, affordable inputs, dependable capacity, and repeat purchasing, while restaurants need a product that performs predictably in the kitchen and can be explained without misleading customers.
The company’s asset-light strategy is intended to address part of that challenge by using regional partners rather than funding a wholly owned factory in every market. The model can expand reach more quickly, although savings on fixed assets may be offset by transfer, qualification, and contract-manufacturing costs.
The first Singapore launch will therefore be a manufacturing test as much as a market test. Regulatory approval confirms that the assessed product met the agency’s safety requirements; it does not establish that the line can produce at commercially sustainable cost or volume.
Aleph Farms is also pursuing approvals in other markets. Its progress in Singapore will be measured through production start-up, batch consistency, restaurant availability, and capacity growth rather than the approval announcement alone.
